Sana Biotechnology Inc

NASDAQ:SANA

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. The company is headquartered in Seattle, Washington and currently employs 383 full-time employees. The company went IPO on 2021-02-04. The firm is focused on creating and delivering engineered cells as medicines for patients. The firm develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. The company focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).